



Update: IBM Watson and Evidence-Based Patient Care

Jeffrey Betts
IBM Healthcare and Life Sciences

Kelowna Conference, June 19, 2012




On February 14, 2011, IBM Watson made history ...



Actress Lisa Kudrow presents IBM's Watson with "Person Of The Year" at the 15th Annual Webby Awards

Watson's Acceptance Speech:

"Person of the Year.....ironic."




What if our doctors had all the evidence they need to deliver highest quality care, every time?



Can we design a computing system that rivals a human's ability to retrieve, analyze and interpret vast amounts of information? How could we use it for clinical decision support?



Evidence: Evolving to support Personalized Healthcare




IBM Watson brings together a set of transformational technologies to drive optimized outcomes

1 Understands natural language and human speech



2 Generates and evaluates hypothesis for better outcomes



3 Adapts and Learns from user selections and responses




...built on a massively parallel probabilistic evidence-based architecture optimized for POWER7

Why is it so hard for computers to understand humans?




	Structured Data	Unstructured Data								
Where was Einstein born?	<table><tr><th>Physicist</th><th>Birth Place</th></tr><tr><td>A. Einstein</td><td>Ulm</td></tr><tr><td>N. Bohr</td><td>Copenhagen</td></tr><tr><td>M. Curie</td><td>Warsaw</td></tr></table> <p>Source: Excel File, Database, etc.</p>	Physicist	Birth Place	A. Einstein	Ulm	N. Bohr	Copenhagen	M. Curie	Warsaw	<p><i>“One day, from among his city views of Ulm, Otto chose a water color to send to Albert Einstein as a remembrance of Einstein’s birthplace”</i></p> <p>Source: http://www.schaeffenacker-ulm.de/en/otto.html</p>
Physicist	Birth Place									
A. Einstein	Ulm									
N. Bohr	Copenhagen									
M. Curie	Warsaw									
Welch ran this?	<table><tr><th>Person</th><th>Organization</th></tr><tr><td>L. Gerstner</td><td>IBM</td></tr><tr><td>J. Welch</td><td>GE</td></tr><tr><td>W. Gates</td><td>Microsoft</td></tr></table> <p>Source: Excel File, Database, etc.</p>	Person	Organization	L. Gerstner	IBM	J. Welch	GE	W. Gates	Microsoft	<p><i>“If leadership is an art then surely Jack Welch has proved himself a master painter during his tenure at GE”</i></p> <p>Source: <i>Jack Welch and the GE Way</i>, Robert Slater</p>
Person	Organization									
L. Gerstner	IBM									
J. Welch	GE									
W. Gates	Microsoft									

IBM Watson Goes Way Beyond Search



How Watson Works



Healthcare Industry is beset with some of the most complex information challenges we collectively face



Medical information is doubling every 5 years, much of which is unstructured



81% of physicians report spending 5 hours or less per month reading medical journals



1 in 5

diagnosis that are estimated to be inaccurate or incomplete



1.5 million

errors in the way medications are prescribed, delivered and taken in the U.S. every year




44,000 -98,000

of Americans who die each year from preventable medical errors in hospitals alone

Cognitive Dispositions to Respond (CDRs) That May Lead to Diagnostic Errors...

- Aggregate bias
- Anchoring
- Ascertainment bias
- Availability
- Base-rate neglect
- Commission bias
- Confirmation bias
- Diagnosis momentum
- Feedback sanction
- Framing effect
- Fundamental attribution error
- Gambler's fallacy
- Gender bias
- Hindsight bias
- Multiple alternatives bias
- Omission bias



Bias Blind Spot: we recognize cognitive bias in others but...

DATE OF ADMISSION: MM/DD/YYYY

DATE OF DISCHARGE: MM/DD/YYYY

ADMITTING DIAGNOSIS: Syncope.

CHIEF COMPLAINT: Sudden lightheadedness.

HISTORY OF PRESENT ILLNESS: This is an (XX)-year-old male with a past medical history of coronary artery disease, CABG done a few years ago, and bilateral nephrolithiasis. He reports a syncopal episode while driving to work. The patient denies chest pain, shortness of breath, or any other symptoms. He has no history of syncope. No nausea or vomiting. No chest pain. No shortness of breath. Came to ER and had a CT head, which was within normal limits. The impression was atrophy with old ischemic changes but no acute intracranial findings. No focal weakness, headache, vision changes or speech changes. The patient has had similar episodes since one year. Peripheral neuropathy since one month. Appetite.

PROCE
thickening
pattern.

CONSULT

PAST ME
hypertens

FAMILY H

SOCIAL H

ALLERGIE

REVIEW O
hemorrh
and feet.

PHYSICAL
Appearan
masses.
rhythm.
smooth n
within no

LABORAT
neutroph
1.6, PTT 3

The patient has a chest x-ray, which showed cardiomegaly, effusion, a left costophrenic angle which has not changed. Head CT, which showed atrophy with old ischemic changes

REFERRING PHYSICIAN: John Doe, MD

CONSULTING PHYSICIAN: Jane Doe, MD

HISTORY OF PRESENT ILLNESS: This (XX)-year-old lady is seen in consultation for Dr. John Doe. She has been under consideration for ventral hernia repair and has a background of aortic valve replacement and known coronary artery disease. The patient was admitted with complaints of abdominal pain, anorexia, and vomiting. She underwent a CT scan of the abdomen and pelvis and this showed the ventral hernia involving the transverse colon, but without strangulation. There was no evidence of a nephrolithiasis. She had bilateral renal cysts. The hepatic flexure wall was thickened. There was no evidence of sigmoid diverticulosis without diverticulitis. It has been recommended to her that she undergo repair of the ventral hernia. For this reason, cardiology consult is obtained to assess whether she can be cared from the cardiac standpoint.

PAST CARDIAC HISTORY: Bypass surgery. She underwent echocardiography and cardiac catheterization prior to the operation. Echocardiography showed an ejection fraction of 50%. There was marked left ventricular hypertrophy with septal wall 1.60 cm and posterior wall 1.55 cm. Coronary arteriography showed 90% stenosis in the anterior descending artery, situated distally just before the apex of the left ventricle. Only mild to moderate narrowing was seen elsewhere in the coronary circulation.

CORONARY RISK FACTORS: Her father had an irregular heartbeat and her brother had a fatal heart attack. She herself has had high blood pressure for 20 years. She has elevated cholesterol and takes Lipitor. She has had diabetes for 20 years. She is not a cigarette smoker. She does little physical exercise.

REVIEW OF SYMPTOMS: CARDIOVASCULAR AND RESPIRATORY: She has no chest pain. She sometimes becomes short of breath if she walks too far. No cough. She has occasional swelling of her feet. Occasionally, she gets mildly lightheaded. Has not lost consciousness. She tends to be aware of her heartbeat when she is tired. She has no history of heart murmur or rheumatic fever.

GASTROINTESTINAL: Recent GI symptoms as noted above, but she does not usually have such problems. She has had no hematemesis. She has no history of ulcer or jaundice. She sometimes has no blood in the stool. **GENITOURINARY:** She tends to have up once at night to pass urine. No dysuria, incontinence. She has had no stones noted. **NEUROLOGIC:** She has occasional headaches. No on, hearing, or speech. No limb weakness. **MUSCULOSKELETAL:** She has no joint pains and has a history of gout. **HEMATOLOGIC:** No anemia, no blood transfusion. **GYNECOLOGIC:** No gynecologic or breast

She has had shoulder and hand injuries and has had carpal tunnel and has been on insulin. She has chronic renal insufficiency with as had hypothyroidism. She has had morbid obesity. She has chronic uses BiPAP. She has had hysterectomy and oophorectomy in the past.

ospital, she was taking glipizide XL 2.5 mg daily, metoprolol 50 mg torvastatin 40 mg daily, Synthroid 75 mcg daily, aspirin 81 mg daily, irrently, she is taking Lipitor 40 mg daily, Lantus 10 units at bedtime, pprol 50 mg b.i.d., and Zosyn 2.25 grams q.6h. es not drink alcohol.

is not currently dyspneic, in no distress. She is alert, oriented, and

nd react normally. No icterus. Mucous membranes well colored. nopathy. Jugular venous pressure not elevated. Carotids equal. per minute and regular and the blood pressure 132/78. The cardiac . There is a grade 3/6 ejection systolic murmur heard medial to the with well heard radiation to the neck vessels.

ussion and auscultation. Normal respiratory effort. der. The presence of a large ventral hernia is noted. e. She has no abdominal pain. She did not feel the lesions are noted.

electrolytes are normal. BUN and creatinine 18/2.2. 7 with hematocrit 34.9, platelets 187,000. in A1c 7.7. TSH 1.82. Troponin I was normal on three occasions. ged heart with postoperative changes, but no evidence of acute ble left atrial enlargement. Low voltage QRS, probable inferior wall terior wall infarction, age undetermined.

with bioprosthetic valve. Residual systolic murmur. ase with severe stenosis in anterior descending artery, but this is s only a small mass of myocardium. ular systolic function. The EKG appearance of previous myocardial , indicating multiple other medical problems as listed above the chart.

It appears that she does not wish to proceed with the if such surgery is not

Unstructured data is messy but filled with key medical facts

Medications, diseases, symptoms, non-symptoms, lab measurements, social history, family history and much more

Cardiology Consultation Transcribed Medical Transcription Sample Reports

DATE OF CONSULTATION: MM/DD/YYYY

REFERRING PHYSICIAN: John Doe, MD

CONSULTING PHYSICIAN: Jane Doe, MD

REASON FOR CONSULTATION: Surgical evaluation for coronary artery disease.

HISTORY OF PRESENT ILLNESS: This is a (XX)-year-old male with a past medical history of coronary artery disease. She underwent percutaneous coronary intervention (PCI) for a stenotic lesion in the left anterior descending artery. Since that time, she has been relatively stable with medical management. However, in the past several weeks, she started to notice some exertional dyspnea with chest pain. For the most part, the pain subsides with rest. For this reason, she was re-evaluated with a cardiac catheterization. The catheterization showed a 70% stenosis in the left anterior descending artery. This was a proximal lesion. The right coronary artery was mildly diseased. The left ventriculogram showed a normal left ventricle. The left ventricular function was mildly reduced with an ejection fraction of about 45%. The left ventriculogram did not show any apical hypokinesis. In view of these findings, surgical consultation was requested and the patient was seen and evaluated by Dr. Doe.

PAST MEDICAL HISTORY: Coronary artery disease as described above with previous PTCA and stenting procedures.

1. Dyslipidemia.
2. Hypertension.
3. Status post breast lumpectomy for cancer with followup radiation therapy to the chest.

ALLERGIES: None.

MEDICATIONS: Aspirin 81 mg daily, Plavix 75 mg daily, Altace 2.5 mg daily, metoprolol 50 mg b.i.d. and Lipitor 10 mg q.h.s.

SOCIAL HISTORY: She quit smoking approximately 8 months ago. Prior to that time, she had about a 35- to 40-pack-year history. She does not abuse alcohol.

FAMILY MEDICAL HISTORY: Mother died prematurely of breast cancer. Her father died prematurely of gastric carcinoma.

REVIEW OF SYMPTOMS: There is no history of any CVAs, TIAs or seizures. No chronic headaches. No asthma, TB, hemoptysis or productive cough. There is no congenital heart abnormality or rheumatic fever history. She has no palpitations. She notes no nausea, vomiting, constipation, diarrhea, but immediately prior to admission, she did develop some diffuse abdominal discomfort. She says that since then, this has resolved. No diabetes or thyroid problems. There is no depression or psychiatric problems. There is no musculoskeletal disorders or history of gout. There are no bleeding problems or blood dyscrasias. No bleeding tendencies. Again, she has a history of breast cancer and status post lumpectomy procedures for this with followup radiation therapy. She has been followed in the past 10 years and mammography shows no evidence of any recurrent problems. There is no recent fevers, malaise, changes in appetite or changes in weight.

PHYSICAL EXAMINATION: Her blood pressure is 120/70, pulse is 80. She is in a sinus rhythm. Her ECG is normal. monitor. Respirations are 18 and unlabored. Temperature is 98.2 degrees Fahrenheit. She weighs 160 pounds, she is 5 feet 4 inches. In general, this was an elderly-appearing, pleasant female who currently is not in acute distress. Skin color and turgor are good. Pupils were equal and reactive to light. Conjunctivae clear. Throat is benign. Mucosa was moist and noncyanotic. Neck veins not distended at 90 degrees. Carotids had 2+ upstrokes bilaterally without bruits. No lymphadenopathy was appreciated. Chest had a normal AP diameter. The lungs were clear in the apices and bases, no wheezing or egophony appreciated. The heart had a normal S1, S2. No murmurs, clicks or gallops. The abdomen was soft, nontender, nondistended. Good bowel sounds present. No hepatosplenomegaly was appreciated. No pulsatile masses were felt. No abdominal bruits were heard. Her pulses are 2+ and equal bilaterally in the upper and lower extremities. No clubbing is appreciated. She is oriented x3. Demonstrated a good amount of strength in the upper and lower extremities. Face was symmetrical. She had a normal gait.

IMPRESSION: This is a (XX)-year-old female with significant multivessel coronary artery disease. The patient also has a left main lesion. She has undergone several PTCA and stenting procedures within the last year to year and a half. At this point, in order to reduce the risk of any possible ischemia in the future, surgical myocardial revascularization is recommended.

PLAN: We will plan to proceed with surgical myocardial revascularization. The risks and benefits of this procedure were explained to the patient. All questions pertaining to this procedure were answered.

Text Analytics – Social History / Smoking Status

NLP of unstructured physician notes found 40% more smokers than previously identified in the structured social history smoking data.



Source: IBM Research study with large clinical care organization in California

Why is Watson Technology ideal for healthcare?

Understands natural language questions



What condition has red eye, pain, inflammation, blurred vision, floating spots and sensitivity to light?

Analyzes large volumes of structured and unstructured data



Physician Notes, Medical Journals, Clinical Trials, EMRs, Pathology Results, Blogs, Wikipedia

Generates and evaluates hypothesis



<u>Possible Diagnosis</u>	<u>Confidence</u>
Uveitis	91%
Iritis	48%
Keratitis	29%

Presents responses with confidence



Supports iterative dialogue to refine results



Family History, Patient Interview, Physical Exam, Current Medications

Learns from results over time





What actions were taken? What treatments were prescribed? What was the outcome?

IBM and Memorial Sloan-Kettering adapting Watson for Oncology

1 in 4

individuals will die from cancer


**3X**rate cancer cost climbs vs. std.
health costs or 15-18% / yr.**20%**of cancer cases receive the
wrong diagnosis initially with
some as high as 44%**75,000**Annual cancer deaths in
Canada

Source: American Cancer Society, National Health Institute, Canadian Cancer Society


The vision for this demonstration was created with the guidance
of the physician experts at Memorial Sloan-Kettering Cancer Center.



Memorial Sloan-Kettering
Cancer Center



Preparation for Doctor's First Consultation with Patient





Patient Details MRN: 040103110830840 Name: Lin J. Yamato Age: 37

SUMMARY | ENCOUNTERS | CONDITIONS | ALLERGIES | MEDICATIONS | LABS | PATHOLOGY | IMMUNIZATIONS | **IMAGING** | PROCEDURES | DOCUMENTS | CLINICAL SUMMARY

Imaging Report

☒ From date: To date:
☐ Last: Units:

Show

Show all

Send to EMR

Reset

Imaging

Report

Imaging Details

Sort By:

- ☒ Modality
☐ Ordered by
☐ Date

Expand all

Collapse all

Chest CT Report

Referring Physician

Dr. Joanne Cameron

Source

N/A


Referral Date

01/05/2012

Electronically Signed

Dr. Joanne Cameron

HIDE IMAGE



Ordered by

Dr. Joanne Cameron

Indication

Abnormal chest x-ray

Status

Signed

MRI +


CT (3) -

CT Chest (2)

02/07/2012:
Joanne Cameron / Chest ▶

CT Abdomen (1)

08/12/2009:
Joanne Cameron / Abdomen



Watson is evaluating patient info against Watson knowledge base...

234 Textbooks



Watson is evaluating patient info against Watson knowledge base...

1,973 Guidelines



Watson is evaluating patient info against Watson knowledge base...

20,274 Journal articles



Watson is evaluating patient info against Watson knowledge base...

4,843 Drug info documents



Watson is evaluating patient info against Watson knowledge base...

1,578 Other clinical documents



Patient Details: NDA# P40107110920810 Name: Lin J. Yamato Age: 37

Case Information



The IBM Watson case information does not obviate the need to review the EMR record in detail



PATIENT

Lin J. Yamato

Patient ID: 000-0000

Provider ID: 00-0000-0

DEMOGRAPHICS

Gender: Female

DOB: Jan 15, 1975 (37)

Place of Birth: Osaka, Japan

CURRENT CONDITION

DX: Lung Adenocarcinoma

Smoking History: Never smoker

Diagnosis

Adenocarcinoma of lung origin

Adenocarcinoma of lung origin

Location

3.1 cm lesion in the right upper lobe of the lung

1.7 cm lesion in the right adrenal gland

Stage

IV Adenocarcinoma

Key Points

2/16/12 – Pathology report from CT biopsy of right adrenal gland: Metastatic adenocarcinoma; morphologically consistent with specimen 312-647



EMR

EVIDENCE

2/07/12 – CT chest/abdomen/pelvis with contrast: 1.7 cm lesion right adrenal gland suspicious for a metastatic deposit



EMR

EVIDENCE

2/05/12 – CT chest without contrast: 3.1 cm lesion right upper lobe of lung suspicious for neoplasm



EMR

EVIDENCE

 **Ask Watson**





Patient Details: MRN: 840103110820840 Name: Lin J. Yamato Age: 37

Case Information



The IBM Watson case information does not obviate the need to review the EMR record in detail



PATIENT

Lin J. Yamato

Patient ID: 000-0000

Provider ID: 00-0000-0

DEMOGRAPHICS

Gender: Female

DOB: Jan 15, 1975 (37)

Place of Birth: Osaka, Japan

CURRENT CONDITION

DX: Lung Adenocarcinoma

Smoking History: Never smoker

morphologically consistent with specimen 312-647



2/07/12 – CT chest/abdomen/pelvis with contrast: 1.7 cm lesion right adrenal gland suspicious for a metastatic deposit



2/05/12 – CT chest without contrast: 3.1 cm lesion right upper lobe of lung suspicious for neoplasm



2/03/12 – SOB, chest tender, cough - labored breathing



Information Needed

Has the patient experienced any hemoptysis?



Does the patient have normal hearing?



Ask Watson





Test Options to Consider



Type of Disease Evaluation



Molecular pathology panel



Extent of Disease Evaluation



MRI of the brain



Pre-treatment Assessment



Baseline EKG



Hepatitis B test



Pregnancy test



WATSON:

Test options are identified based on information available.

Request Pre-auth



Ask Watson





Patient Details: MRN: 840102110830840 Name: Lin J. Yamato Age: 37

Test Options to Consider



WATSON

Test options are based on information available.

Request Pre

Molecular pathology panel

Reason for suggestion

Due to frequent presence of driver mutations in patients with lung cancers, it is recommended that all patients are tested for EGFR, KRAS, ALK mutations.

References

NCGN Guidelines™ Version 3.2011 NSCL-13: EGFR mutation testing (category 1)



VIEW



REMOVE

MSK Best Practice: Test for KRAS in addition to EGFR and ALK



VIEW



REMOVE

D' Angelo et al. Incidence of EGFR exon 18 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. *Journal of Clinical Oncology*. 2011 May; 29(15): 2066-70



VIEW



Ask Watson





Test Options to Consider



WATSON

Test options are based on information available.

Request Prescribed

Molecular Reference

Reason for

Due to frequent lung cancers for EGFR, KR

Purpose: EGFR mutations underlie the sensitivity of lung cancers to erlotinib and gefitinib and can occur in any patient with this illness. Here we examine the frequency of EGFR mutations in smokers and men.

Results: We tested 2,142 lung adenocarcinoma specimens for the presence of EGFR exon 19 deletions and L858R. EGFR mutations were found in 15% of tumors from former smokers (181 of 1,218; 95% CI, 13% to 17%), 6% from current smokers (20 of 344; 95% CI, 4% to 9%), and 52% from never smokers (302 of 580; 95% CI, 48% to 56%; $P < .001$ for ever v never smokers). EGFR mutations in former or current smokers represented 40% of all those detected (201 of 503; 95% CI, 36% to 44%). EGFR mutations were found in 19% (157 of 827; 95% CI, 16% to 22%) of tumors from men and 26% (346 of 1,315; 95% CI, 24% to 29%) of tumors from women ($P < .001$). EGFR mutations in men represented 31% (157 of 503; 95% CI, 27% to 35%) of all those detected.

Conclusion: A large number of EGFR mutations are found in adenocarcinoma tumor specimens from men and people who smoked cigarettes. If only women who were never smokers were tested, 57% of all EGFR mutations would be missed. Testing for EGFR mutations should be considered for all patients with adenocarcinoma of the lung at diagnosis, regardless of clinical characteristics. This strategy can extend the use of EGFR tyrosine kinase inhibitors to the greatest number of individuals with the potential for substantial benefit.

Ask Watson





Treatment Options to Consider



Identified Options

WATSON:

Insufficient information
is available to provide
treatment options
with high confidence.

See the Test Options tab
for additional tests that
would provide the
needed information.

[Request Pre-auth](#)


	Treatment plan 1 Systemic Chemo: Cisplatin, Pemetrexed, Bevacizumab	Confidence 32% 	TBD match with patient preferences	 EVIDENCE
	Treatment plan 2 Systemic Chemo: Carboplatin, Paclitaxel, Bevacizumab	Confidence 30% 	TBD match with patient preferences	 EVIDENCE
	Treatment plan 3 Systemic Chemo: Erlotinib	Confidence 28% 	TBD match with patient preferences	 EVIDENCE
Radiation and Surgery are unlikely to be appropriate.				 EVIDENCE

Ask Watson




First Consultation

- Case is discussed with patient
- Patient preferences discussed
- Patient is examined
- Tests are ordered



Preparation for Doctor's Second Consultation with Patient

- ▶ 10 days have elapsed since the first consultation
- ▶ Test results are now available





Patient Details MRN: 040103110830840 Name: Lin J. Yamato Age: 37

[SUMMARY](#) | [ENCOUNTERS](#) | [CONDITIONS](#) | [ALLERGIES](#) | [MEDICATIONS](#) | [LABS](#) | [PATHOLOGY](#) | [IMMUNIZATIONS](#) | **[IMAGING](#)** | [PROCEDURES](#) | [DOCUMENTS](#) | [CLINICAL SUMMARY](#)

Imaging Report

☒ From date: To date:
☐ Last: Units:

Show

Show all

Send to EMR

Reset

Imaging

Sort By:

- ☒ Modality
☐ Ordered by
☐ Date

Expand all

Collapse all

CT (3) +

MRI (1) -

MRI Brain (1)

03/01/2012:
Mark Kris / Brain

Report

Brain MRI Report

Referring Physician

Dr. Mark Kris

Source

N/A


Referral Date

01/05/2012

Electronically Signed

Dr. Joanne Cameron

HIDE IMAGE -



Imaging Details

Ordered by

Dr. Mark Kris

Indication

Rule out brain metastasis

Status

Signed



Patient Details: MRN: 840103110830840 Name: Lin J. Yamato Age: 37

Case Information



The IBM Watson case information does not obviate the need to review the EMR record in detail



PATIENT

Lin J. Yamato

Patient ID: 000-0000

Provider ID: 00-0000-0

DEMOGRAPHICS

Gender: Female

DOB: Jan 15, 1975 (37)

Place of Birth: Osaka, Japan

CURRENT CONDITION

DX: Lung Adenocarcinoma

Smoking History: Never smoker

Diagnosis

Adenocarcinoma of lung origin

Adenocarcinoma of lung origin

Location

3.1 cm lesion in the right upper lobe of the lung

1.7 cm lesion in the right adrenal gland

Stage

T2N0M1

Key Points *2 Updates

* 03/06/12 – Molecular pathology shows EGFR exon 20 insertion



EMR



EVIDENCE

* 03/01/12 – Brain MRI is negative for metastases



EMR



EVIDENCE

2/16/12 – Pathology report from CT biopsy of right adrenal gland: Metastatic adenocarcinoma; morphologically consistent with specimen 312-647



Ask Watson





Treatment Options to Consider



Identified Options

WATSON:

Treatment options are listed based on the information available.

Request Pre-auth

	Treatment plan 1 Systemic Chemo: Cisplatin, Pemetrexed, Bevacizumab	Confidence 95% 	Acceptable match with patient preferences	 EVIDENCE
	Treatment plan 2 Systemic Chemo: Carboplatin, Paclitaxel, Bevacizumab	Confidence 45% 	Unacceptable match with patient preferences	 EVIDENCE
	Treatment plan 3 Systemic Chemo: Erlotinib	Confidence 8% 	Preferred match with patient preferences	 EVIDENCE

Radiation and Surgery are unlikely to be appropriate.



Ask Watson





Treatment Options to Consider



WATSON

Treatment options are listed based on information available.

Request Prescription

Treatment plan 1

Reason for suggestion

Stage IV disease requires systemic therapy. Since the tumor harbors EGFR TKI resistant mutation, the recommended treatment is Cisplatin, Pemetrexed, and Bevacizumab.

Surgery: not recommended for this patient due to the presence of metastatic disease.

RT: not recommended for this patient due to the presence of metastatic disease.

Of the medically appropriate regimens, this treatment is least likely to cause alopecia.

Usage Statistics:

This treatment plan has been selected 154 times out of 257 similar patient cases.

References

NCCN Guidelines™ Version 3.2011
NSCL-14: Adenocarcinoma, Large Cell,
NSCLC NOS: EGFR mutation negative OR
unknown



VIEW



REMOVE

Wu et al. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations is Associated with Poor Gefitinib Treatment Response. *Clinical Cancer Research*. 2008 14:4877-4882



VIEW



REMOVE

Wu et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. *Clinical Cancer Research*. 2011 Jun 1; 17(11): 3812-21.



VIEW




REMOVE



Ask Watson



Second Consultation





Treatment Options to Consider



WATSON:

Treatment options are listed based on the information available.

Request Pre-auth

Identified Options

	Treatment plan 1 Systemic Chemo: Cisplatin, Pemetrexed, Bevacizumab	Confidence 95% 	Acceptable match with patient preferences	 EVIDENCE
	Treatment plan 2 Systemic Chemo: Carboplatin, Paclitaxel, Bevacizumab	Confidence 45% 	Unacceptable match with patient preferences	 EVIDENCE
	Treatment plan 3 Systemic Chemo: Erlotinib	Confidence 8% 	Preferred match with patient preferences	 EVIDENCE
Radiation and Surgery are unlikely to be appropriate.				



Ask Watson






Treatment Options to Consider



Ask Watson



Watson is listening...



FINISHED SPEAKING



CANCEL



Patient Details: MRN: 540103110830840 Name: Lin J. Yamato Age: 37

Treatment Options to Consider



Ask Watson



Mrs. Yamato experienced 2 tablespoons of hemoptysis yesterday. How does that change her treatment options?



RETRY



SUBMIT



CANCEL



Treatment Options to Consider




Ask Watson



Dr. Mark Kris

Mrs. Yamato experienced 2 tablespoons of hemoptysis yesterday. How does that change her treatment options?



Watson is gathering information...



Treatment Options to Consider



Ask Watson



Dr. Mark Kris:

Mrs. Yamato experienced 2 tablespoons of hemoptysis yesterday. How does that change her treatment options?

WATSON

Apply to the case

Ignore

Revised

Treatment Plan 1:

Gisplatin, Pemetrexed

Treatment Plan 2:

Carboplatin, Pemetrexed

Treatment Plan 3:

Carboplatin, Paclitaxel

Treatment Plan 4:

Erlotinib

Original

Treatment Plan 1:

Gisplatin, Pemetrexed, Bevacizumab

Treatment Plan 2:

Carboplatin, Paclitaxel, Bevacizumab

Treatment Plan 3:

Erlotinib



EVIDENCE



Treatment Options to Consider



WATSON:

Treatment options are listed based on the information available.

[Order](#)

Identified Options


	Treatment plan 1 Systemic Chemo: Cisplatin, Pemetrexed	Confidence 90% 	Acceptable match with patient preferences	 EVIDENCE
	Treatment plan 2 Systemic Chemo: Carboplatin, Pemetrexed	Confidence 25% 	Acceptable match with patient preferences	 EVIDENCE
	Treatment plan 3 Systemic Chemo: Carboplatin, Paclitaxel	Confidence 25% 	Unacceptable match with patient preferences	 EVIDENCE
	Treatment plan 4 Systemic Chemo: Erlotinib	Confidence 0% 	Preferred match with patient preferences	



Ask Watson



A Range of Watson-enabled Healthcare Solutions




Patient

Caregiver...Nurse...Physician Assistant


Clinician

Learning systems are ushering a new era of computing

Cognitive Computing



Programmatic Computing



Emerging IT

- Structured & unstructured (global)
- Probabilistic Applications
- Discovery Oriented
- Natural Language
- Systems of engagement

Traditional IT

- Structured data (local)
- Deterministic Applications
- Search Oriented
- Machine Language
- Systems of records

Tabulation



1900-

1950-

2011-

Thank
You